Multibacillary leprosy

Summary

Multibacillary leprosy (MONDO:0041751) is a disease and 3 clinical trials. Top therapeutic interventions include acetylcholine and clofazimine. A subtype of leprosy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	multibacillary leprosy
Mondo ID	MONDO:0041751
MeSH	D056006
ICD-11	1123804548
SNOMED CT	416257001
UMLS	C1562585
MedGen	288329
GARD	0025838
Is cancer (heuristic)	no

Also known as: lepromatous leprosy · multibacillary leprosy

Disease family

This is a subtype of leprosy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › leprosy › multibacillary leprosy

Related subtypes (5): indeterminate leprosy, borderline leprosy, tuberculoid leprosy, lepromatous leprosy, paucibacillary leprosy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01290744	PHASE4	COMPLETED	Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy
NCT07448389	Not specified	NOT_YET_RECRUITING	Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Hansen’s Disease in Costa Rica (2018-2025)
NCT02085317	Not specified	COMPLETED	Microcirculatory Impairment in Patients With Leprosy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ACETYLCHOLINE	4	1
CLOFAZIMINE	4	1